

CLAIMS

1. Use of an ophthalmic composition in the manufacture of a medicament for inhibiting or reversing the progression of cataract formation, presbyopia, or age related degeneration of a crystalline lens in an eye, wherein the composition is to contact the eye, including the crystalline lens, said composition comprising at least one γ-crystallin charge masking agent,

wherein the γ-crystallin charge masking agent is



or



.


2. The use according to claim 1, wherein the reactive group is NH_2, N-hydroxysuccinimide or COOH.


3. The use according to claims 1 or 2, wherein the medicament is an eye drop or is to be administered with an ophthalmic device.

4. The use according to claim 3, wherein the ophthalmic device is a contact lens or a punctal plug.

5. The use according to claims 1 or 2, wherein said medicament is to be administered by injection, iontophoresis or ultrasound enhancement.

6. An ophthalmic composition comprising a bifunctional molecule, wherein the bifunctional molecule is



or


.

7. The ophthalmic composition of claim 6, wherein the reactive group is NH_2, N-hydroxysuccinimide or COOH.

8. The ophthalmic composition of claim 6, wherein the ophthalmic composition is an eye drop or comprised within an ophthalmic device.

9. The ophthalmic composition of claim 8, wherein the ophthalmic device is a contact lens or a punctal plug.